Guardion Health Sciences Inc (GHSI)

[FROZENFLAME]

.435 AH

[FROZENFLAME]

I think something else, maybe Coronavirus !!!

[Viewmont]

Is all the spike because of earnings coming out on tomorrow March 19, 2020 or is there any new news out?

[FROZENFLAME]

Tons of buying $$$$

[LivinLarge8]

News coming hold em

[FROZENFLAME]

Nice looks like news after hours .

[FROZENFLAME]

What’s going NEWS !!!

[jackson73]

.40 break! lets gooo

[jackson73]

.38's goin lets see a .40 break n run

[nunodigital]

It’s going to keep moving to the next day until actual news, Er, pr, whichever it is actually posts...

[Viewmont]

Yes it does look like they forgot or they don't have a set date or they don't take it seriously or they keep postponing. LOL. Here's what I found.

Guardion Health Sciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 19th, 2020 based off prior year's report dates.

https://www.marketbeat.com/stocks/NASDAQ/GHSI/earnings/

[cep2535]

Hmmmm must have forgot about it lol

[Viewmont]

It says before market central standard time.

[cep2535]

What time? Today is the 17th

[Viewmont]

San Diego, California - March 6, 2020 - Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (Nasdaq: GHSI), an ocular health sciences company that develops, formulates, manufacture and distributes condition-specific medical foods supported by evidence-based protocols, today announced that it has received total gross proceeds of $3,510,630.00 during the period from February 28, 2020 through March 3, 2020 from the exercise of 10,265,000 warrants issued in the Company’s October 2019 follow-on offering at an exercise price of $0.342 per share.

Proceeds from exercise of the warrants are being utilized to fund Guardion’s efforts to develop new products, market and distribute both existing and new products, and for working capital and general corporate purposes.

The Company has approximately 85,247,562 common shares currently issued and outstanding.

“We are pleased with the participation of our shareholders and are grateful for their continued support,” commented Michael Favish, CEO of Guardion. “Building on this momentum, we expect to increase awareness of our existing products through a robust marketing effort, while working to develop new products to add to our growing portfolio.”

[Viewmont]

Share Structure
Market Cap calculated only for this class of securities.
Market Cap Market Cap
25,419,089
03/13/2020
Authorized Shares
Not Available
Outstanding Shares
74,982,562
11/13/2019
Restricted
Not Available
Unrestricted
Not Available
Held at DTC
Not Available
Float
Not Available
Par Value
No Par Value

[Viewmont]

TDA is now posting that earnings report is on 3/17/20

[nunodigital]

Guess we’ll see on Monday

[Viewmont]

They posted it later that earnings report is postponed to 3/16/20.

[nunodigital]

No ER today

[Viewmont]

Earnings on 3/12/20 before market Central Standard Time.

[FROZENFLAME]

Loading up waiting for the company to to release news about COVID-19 !!!

[Viewmont]

Previous news! Guardion Health Sciences Selected by Malaysian Listed Company to Develop an Immuno-Supportive Formula
GlobeNewswire GlobeNewswire•February 26, 2020
Guardion® has signed a Letter of Appointment with Ho Wah Genting Berhad (HWGB) to create a new formula, designed to enhance the immune system.
The formula will be a unique and exclusive brand of HWGB

San Diego, California, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc (“Guardion” or the “Company”) (GHSI) announced that Ho Wah Genting Berhad (“HWGB”) a Malaysian company listed on the Malaysian Stock Exchange (Industrial Products sector) has selected Guardion to develop an immune- supportive formula for their consumer base. HWGB has contracted Guardion and its recently acquired subsidiary NutriGuard, to develop a proprietary formula to meet the demands of their customers for an immune-supportive product.

Professor Mark McCarty, the original founder of NutriGuard, and now a senior scientist consultant to Guardion, is a leader in the scientific validation of nutrition-based therapies for potentiating the type 1 interferon response to RNA viruses. Boosting type 1 interferon response is believed to blunt the replication of virus cells. Dr McCarty has been tasked with developing this proprietary formula for HWGB.

The formula is designed to provide both immuno-supportive and anti-inflammatory benefits to its users. The formula has not been used nor tested, nor is it intended to specifically address symptoms of the current COVID-19 virus.

Michael Favish, CEO of Guardion Health Sciences, stated “We are pleased to partner with Ho Wah Genting Berhad for the development of a product specifically designed to boost the immune system capability, i.e. type 1 interferon response, to RNA viruses.”

Dato’ Aaron Lim, group CEO for Ho Wah Genting Berhad, commented, “We are anxious to be able to deliver a unique product that can provide a timely and effective immune response to our customer base. I would like to thank Guardion Health Sciences for their assistance and responsiveness to this request and look forward to introducing this much needed product to the market.”

About Guardion Health Sciences, Inc.

Guardion is an ocular health sciences company thar develops, formulates, manufacture and distributes condition-specific medical foods supported by evidence-based protocols. Guardion’s initial medical food product, Lumega-Z, addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”) and a significant component of functional vision performance. Guardion has also developed a proprietary medical device, the MapcatSF®, which accurately measures the macular pigment density, therefore providing the only two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the SEC at www.sec.gov.

About VectorVision®

VectorVision® specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision®’s CSV-1000 device is considered the standard of care for clinical trials. VectorVision® is a wholly owned subsidiary of Guardion.

Guardion has completed development of the proprietary VectorVision® CSV-2000 standardized contrast sensitivity test and recently introduced the commercial product to the marketplace. The CSV-2000 is the only computer-generated vision testing instrument available that will provide the optical marketplace with the Company’s proprietary, industry-standard contrast sensitivity test, along with a full suite of standard vision testing protocols. The proprietary standardization methodology incorporated into the CSV-2000 includes a patented technology known as AcQviz that automatically and constantly measures and adjusts screen luminance to a fixed standard light level for vision testing.

About NutriGuard

NutriGuard formulates high-quality, scientifically credible nutraceuticals, which are designed to supplement consumers’ diets and assist in the prevention and management of an array of diseases and conditions. NutriGuard uses pharmaceutical standards to establish the safety and efficacy of the products it develops and markets, and also maintains that commitment through rigorous manufacturing and quality assurance programs. Guardion plans to increase NutriGuard’s existing customer base and build on its product platform by making NutriGuard products available to patients directly and through recommendations by their physicians.

[FROZENFLAME]

Time to buy the dip .

[Viewmont]

Previous news! Guardion Health Sciences Selected by Malaysian Listed Company to Develop an Immuno-Supportive Formula
GlobeNewswire GlobeNewswire•February 26, 2020
Guardion® has signed a Letter of Appointment with Ho Wah Genting Berhad (HWGB) to create a new formula, designed to enhance the immune system.
The formula will be a unique and exclusive brand of HWGB

San Diego, California, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc (“Guardion” or the “Company”) (GHSI) announced that Ho Wah Genting Berhad (“HWGB”) a Malaysian company listed on the Malaysian Stock Exchange (Industrial Products sector) has selected Guardion to develop an immune- supportive formula for their consumer base. HWGB has contracted Guardion and its recently acquired subsidiary NutriGuard, to develop a proprietary formula to meet the demands of their customers for an immune-supportive product.

Professor Mark McCarty, the original founder of NutriGuard, and now a senior scientist consultant to Guardion, is a leader in the scientific validation of nutrition-based therapies for potentiating the type 1 interferon response to RNA viruses. Boosting type 1 interferon response is believed to blunt the replication of virus cells. Dr McCarty has been tasked with developing this proprietary formula for HWGB.

The formula is designed to provide both immuno-supportive and anti-inflammatory benefits to its users. The formula has not been used nor tested, nor is it intended to specifically address symptoms of the current COVID-19 virus.

Michael Favish, CEO of Guardion Health Sciences, stated “We are pleased to partner with Ho Wah Genting Berhad for the development of a product specifically designed to boost the immune system capability, i.e. type 1 interferon response, to RNA viruses.”

Dato’ Aaron Lim, group CEO for Ho Wah Genting Berhad, commented, “We are anxious to be able to deliver a unique product that can provide a timely and effective immune response to our customer base. I would like to thank Guardion Health Sciences for their assistance and responsiveness to this request and look forward to introducing this much needed product to the market.”

[Viewmont]

Guardion Health Sciences Receives $3.5 Million from Exercise of Warrants
GlobeNewswire GlobeNewswire•March 6, 2020
San Diego, California, March 06, 2020 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (“Guardion” or the “Company”) (GHSI), an ocular health sciences company that develops, formulates, manufacture and distributes condition-specific medical foods supported by evidence-based protocols, today announced that it has received total gross proceeds of $3,510,630.00 during the period from February 28, 2020 through March 3, 2020 from the exercise of 10,265,000 warrants issued in the Company’s October 2019 follow-on offering at an exercise price of $0.342 per share.

Proceeds from exercise of the warrants are being utilized to fund Guardion’s efforts to develop new products, market and distribute both existing and new products, and for working capital and general corporate purposes.

The Company has approximately 85,247,562 common shares currently issued and outstanding.

“We are pleased with the participation of our shareholders and are grateful for their continued support,” commented Michael Favish, CEO of Guardion. “Building on this momentum, we expect to increase awareness of our existing products through a robust marketing effort, while working to develop new products to add to our growing portfolio.”

About Guardion Health Sciences, Inc.

Guardion® is an ocular health sciences company that develops, formulates, manufacture and distributes condition-specific medical foods supported by evidence-based protocols. Guardion’s initial medical food product, Lumega-Z, addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”) and a significant component of functional vision performance. Guardion has also developed a proprietary medical device, the MapcatSF®, which accurately measures the macular pigment density, therefore providing the only two-pronged evidence-based protocol for the treatment of a depleted macular protective pigment. Information and risk factors with respect to Guardion and its business, including its ability to successfully develop and commercialize its proprietary products and technologies, may be obtained in the Company’s filings with the SEC at www.sec.gov.

About VectorVision®

VectorVision® specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision’s® patented technology is considered the standard of care for clinical trials. VectorVision® is a wholly owned subsidiary of Guardion.

Guardion has completed development of the proprietary VectorVision® CSV-2000 standardized contrast sensitivity test and recently introduced the commercial product to the marketplace. The CSV-2000 is the only computer-generated vision testing instrument available that will provide the optical marketplace with the Company’s proprietary, industry-standard contrast sensitivity test, along with a full suite of standard vision testing protocols. The proprietary standardization methodology incorporated into the CSV-2000 includes a patented technology known as AcQviz that automatically and constantly measures and adjusts screen luminance to a fixed standard light level for vision testing.

About NutriGuardTM

NutriGuardTM formulates high-quality, scientifically credible nutraceuticals, which are designed to supplement consumers’ diets and assist in the prevention and management of an array of diseases and conditions. NutriGuard uses pharmaceutical standards to establish the safety and efficacy of the products it develops and markets, and also maintains that commitment through rigorous manufacturing and quality assurance programs. Guardion plans to increase NutriGuard’s existing customer base and build on its product platform by making NutriGuard products available to patients directly and through recommendations by their physicians.

[FROZENFLAME]

https://www.npr.org/sections/health-shots/2020/03/06/812964894/where-that-8-3-billion-in-u-s-coronavirus-funding-will-and-wont-go

[EESPINOZA]

Next week will be great. GLTA

[dirtydozen911]

8K OUT ...supporting the p r this morning.....the 10 million warrants have been exercised ,( from the October offering ) giving the company an additional 3.5 million in working capital

a subsid of the company claims to have a product for lung infections , and virus prevention......avail to buy in april

maybe the company should send a sample to the C D C for evaluation in treatment of the coronavirus...…..gl

[LivinLarge8]

.50 break and this rocks

[dirtydozen911]

SH** show...sh** show...……...shorty SH** show....gl

[dirtydozen911]

700k on the bid right now....no one is taking the bait...

SH** show...sh** show....gl

[dirtydozen911]

scanner just picked up a spike on this …..looks like $300- $400 thousand bid support......maybe the sh** show is over..?????

[dirtydozen911]

was thinking about getting in a couple minutes ago......DON`T WASTE YOUR TIME OR MONEY!!…….just a mm SHORTIN SH** SHOW....GLTA

[weedtrader420]

WOOHOOOOOOOOO $$GHSI$$ $1.25 TARGET PRICE TODAY

[marcnuke]

Pretty sure earnings before the bell. In line or slightly above. Premarket tomorrow will break .50’s. Enjoy the ride!

[eebbee]

We have new high of day here afterhours.

[Widowsson32]

Senate passes $8.3 billion coronavirus bill, sending it to Trump | TheHill
https://thehill.com/homenews/senate/486147-senate-passes-83-billion-coronavirus-bill-sending-it-to-trump

[mr_freemoney]

Based on what? That's not what I'm seeing.

[Widowsson32]

Turned out to be a pump n dump lmaooo

[Widowsson32]

Nasdaq ssr list for today Short Sale Circuit Breaker
https://www.nasdaqtrader.com/trader.aspx?id=ShortSaleCircuitBreaker

[ClayTrader]

* * $GHSI Video Chart 03-03-2020 * *

Link to Video - click here to watch the technical chart video

[Widowsson32]

I noticed recently lot of fake companies were getting pumped but this is not fake this is a real CV pharmaceutical company

[Timetravelerdos]

Totally agree. The first company will be an amazing win for investors. That is why I have several. Just like buying lottery tickets!

[BeasTrader]

what happen? going wrong way

[Widowsson32]

Word on the street is which ever pharmaceutical company comes with the cure for CV it will be like hitting a trillion dollar Jack pot

[Seann]

PM or regular market open? And can you guarantee? Lol

[LivinLarge8]

.60+ open tomorrow

[Timetravelerdos]

Strong Buying GHSI closing out today! Well done.

[Widowsson32]

Lot of money from the institutions will be moving to the pharmaceutical sector in the stock market.. You're seeing pre movement of funds by institutions in the pharmaceutical sector This will get crazy